CAMP4 Therapeutics Corp. (CAMP), a clinical-stage biopharmaceutical company, Thursday, provided an update on its lead investigational asset CMP-CPS-001.
CMP-CPS-001 is an antisense oligonucleotide therapeutic candidate for treating Urea Cycle Disorders (UCD), a rare genetic metabolic disorder that prevents the body from safely removing ammonia.
A phase I trial evaluating the safety, tolerability, and pharmacokinetics of CMP-CPS-001 in healthy volunteers in Australia is underway. The study includes single- and multiple-ascending dose cohorts.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.